Nepicastat for Hyper-arousal in PTSD in Combat Veterans

This clinical trial focuses on treating Post Traumatic Stress Disorder (PTSD), specifically in veterans who have served in conflict zones at least once between 1990 and 2008. The main goal is to evaluate the effectiveness of a drug called nepicastat in managing hyper-arousal, a common symptom of PTSD. The study also aims to see if nepicastat can induce PTSD remission, improve other PTSD symptoms, and enhance the quality of life and overall functioning of the participants. The importance of this study lies in its potential to define a better approach to treating PTSD and improving the lives of affected veterans and active military service members. The study lasts for 6 weeks. Participants will receive either nepicastat or a placebo. The primary outcome measured is the change from the start of the study in the hyperarousal scores, as assessed by a tool called CAPS(D). This will help determine if nepicastat is more effective than a placebo in managing this symptom. The study also aims to evaluate the tolerability and side effects of nepicastat in the treatment of PTSD. The results from this pilot study will help in developing new treatment strategies for future larger studies.